Navigation Links
Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
Date:8/31/2010

PHILADELPHIA and LONDON, Sept. 1 /PRNewswire/ -- Thomson Reuters and Rondaxe Enterprises today announced an agreement that will enable professionals working in the generic drug sector to better estimate the cost of manufacturing active pharmaceutical ingredients (API).

Information on the costs associated with manufacturing APIs is vital for generic drug companies and API manufacturers around the world, which operate in an intensely price competitive market. Choosing the right drugs to develop and launch is imperative and can determine the difference between profitable or unprofitable products.

Under the terms of the arrangement, patent and synthesis route data from Thomson Reuters will be combined with leading cost-of-goods (CoG) modeling tools from Rondaxe. This will allow professionals working in portfolio selection, research and development, as well as process chemists and engineers, to model drug manufacturing processes and to perform cost analysis simulations.

"We are delighted to partner with Rondaxe to strengthen our services to the generic and API manufacturing market," said Claude Bassett, vice president of Specialty Markets at Thomson Reuters. "The partnership enables us to meet a demand from our clients for greater insight into the costs associated with manufacturing an API, which are often the most significant factor in the cost of goods of the finished generic drug."

Ken Shultis, CEO at Rondaxe Enterprises said; "We are excited to bring together our cost-of-goods expertise, augmented by our CoGs software product, with the leading information from Thomson Reuters in order to benefit pharmaceutical and biotech companies around the world."

Customers using the Newport suite of products from Thomson Reuters will be able to request cost analyses from Rondaxe directly within the product.

For more information about the Newport line of products, please visit:

http://go.thomsonreuters.com/globalgenerics

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.  For more information, go to www.thomsonreuters.com.

About Rondaxe Enterprises

Rondaxe Enterprises is a unique company providing a suite of services that combines expert drug development consulting, in-depth project management leadership, software applications and virtual business development designed specifically for emerging pharmaceutical and biotech companies. Rondaxe is led by four managing members, a team of experienced industry executives and more than 50 senior advisors, most of whom have 15-30 plus years of industry experience, with a vision and an unflinching dedication to clients' success. Founded in 2003, Rondaxe has enjoyed steady growth based on a proven track record in delivering results, establishing solid relationships with customers, and a strong commitment to expand skills and product offerings as customer's needs expand.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Barr Receives Approval for Generic Version of Razadyne(R) Tablets
2. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
3. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
4. BioComp Pharma Launches First Generic Drug for Tindamax(R)
5. Hospira Supports Newly Introduced Biogenerics Legislation
6. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
7. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
(Date:4/27/2016)... ... , ... Shimadzu Scientific Instruments (SSI) will be showcasing a ... and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, ... by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of Directors of ... John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, ... leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton ...
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology ... development initiatives for potential stem cell protocol management for 2016 – 2020. , ... meeting to establish a working agenda and foster initiatives to promote stem cell research ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):